Yong Zang

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 17

Top Topics

Finite Element Analysis

Immune Response

Top Venues

Clinical trials (London, England)

Statistics in medicine

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Peter F Thall, Ying Yuan
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80 (1) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Peter F Thall, Ying Yuan
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80 (1) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Peter F Thall, Ying Yuan
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80 (1) (2024)
Namita Agrawal, Jack M Shireman, Kevin Shiue, Aaron Kamer, LaKeisha Boyd, Yong Zang, Neel Mukherjee, James Miller, Charles Kulwin, Aaron Cohen-Gadol, Troy Payner, Chih-Ta Lin, Jesse J Savage, Brandon Lane, Bradley Bohnstedt, Tim Lautenschlaeger, Naoyuki Saito, Mitesh Shah, Gordon Watson, Mahua Dey
Preoperative stereotactic radiosurgery for patients with 1-4 brain metastases: A single-arm phase 2 trial outcome analysis (NCT03398694). Neuro-oncology practice 11 (5) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Yong Zang, Ying Yuan
Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical statistics (2023)
Peter F Thall, Yong Zang, Andrew Genius Chapple, Ying Yuan, Ruitao Lin, David Marin, Pavlos Msaouel
Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Beibei Guo, Yong Zang
BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint. Statistics in medicine (2021)
Beibei Guo, Yong Zang
BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy. Statistics in medicine 39 (29) (2020)
Yifei Zhang, Sha Cao, Chi Zhang, Ick Hoon Jin, Yong Zang
A Bayesian adaptive phase I/II clinical trial design with late-onset competing risk outcomes. Biometrics 77 (3) (2020)
Yan Han, Hao Liu, Sha Cao, Chi Zhang, Yong Zang
TSNP: A two-stage nonparametric phase I/II clinical trial design for immunotherapy. Pharmaceutical statistics 20 (2) (2020)
Yong Zang, Beibei Guo, Yan Han, Sha Cao, Chi Zhang
A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling. Statistics in medicine 38 (15) (2019)